NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1.
NY-BR-1 p904 A2 is a synthetic peptide derived from the NY-BR-1 antigen, a breast cancer-associated protein that has garnered significant attention in tumor antigen research. As a defined peptide fragment, it represents a specific sequence within the NY-BR-1 protein, enabling precise investigation of antigenic properties, epitope mapping, and immunological responses. Its molecular design and relevance to tumor-associated antigens make it a valuable tool for studies focused on cancer immunology, biomarker discovery, and peptide-based assay development. Researchers utilize such synthetic peptides to dissect protein function, study immune recognition, and develop robust analytical methodologies in the context of oncology and immunodiagnostics.
Epitope Mapping: NY-BR-1 p904 A2 is frequently employed in epitope mapping studies to identify and characterize immunodominant regions within the NY-BR-1 protein. By synthesizing and testing defined peptide sequences, investigators can pinpoint specific amino acid motifs recognized by antibodies or T-cell receptors. This approach is critical for understanding the molecular basis of immune recognition and for the rational design of peptide-based tools in cancer immunology.
Immunoassay Development: The defined sequence of this peptide facilitates its use as a standard or capture reagent in immunoassays, such as ELISA or peptide microarrays, aimed at detecting NY-BR-1-specific antibodies or T-cell responses in biological samples. Its incorporation into assay platforms supports the quantitative and qualitative assessment of immune responses, thereby advancing research in tumor antigenicity, immune profiling, and the evaluation of candidate biomarkers in oncology research.
Antigen-Specific T-Cell Studies: Researchers utilize NY-BR-1 p904 A2 to stimulate and monitor antigen-specific T-cell responses in vitro. By exposing peripheral blood mononuclear cells or isolated T lymphocytes to the peptide, it is possible to assess T-cell activation, cytokine production, and cytotoxic potential against NY-BR-1-expressing targets. Such investigations are instrumental in elucidating the cellular immune mechanisms underlying tumor recognition and in guiding the development of peptide-based immunotherapeutic strategies.
Peptide-Protein Interaction Analysis: The synthetic nature of NY-BR-1 p904 A2 allows for its application in binding assays to study peptide-protein interactions, such as those involving major histocompatibility complex (MHC) molecules or antibody binding domains. Detailed analysis of these interactions provides insight into the structural determinants of antigen presentation and recognition, supporting both fundamental research and the rational design of immunological reagents.
Analytical Method Validation: As a chemically defined peptide, NY-BR-1 p904 A2 serves as a valuable reference standard or positive control in analytical method development and validation. Its use ensures the reliability and reproducibility of peptide quantification, detection, and characterization protocols, particularly in the context of quality control, assay calibration, and the standardization of immunological assays targeting NY-BR-1 or related tumor-associated antigens.
2. High fat diet and GLP-1 drugs induce pancreatic injury in mice
3. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
4. TMEM16F and dynamins control expansive plasma membrane reservoirs
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More